BACKGROUND: Alzheimer's disease (AD) is characterized by a number of serious and debilitating behavioral and psychological symptoms of dementia (BPSD). The most common of these BPSD is apathy, which represents a major source of morbidity and premature institutionalization in the AD population. Many studies have identified discrete changes to the dopaminergic (DAergic) system in patients with AD. The DAergic system is closely related to the brain reward system (BRS) and some studies have suggested that dysfunction in the DAergic system may account for symptoms of apathy in the AD population. METHOD: Changes to the dopamine (DA) system in AD will be reviewed, and evidence supporting the involvement of the DAergic system in the development of apathy will be examined. Additionally, some pharmacological interventions with DA activity have been identified. The utility of these treatments in the AD population will be reviewed, with a focus on apathy as an outcome. RESULTS: Evidence presented in this review suggests that DA dysfunction in discrete brain areas is an important correlate of apathy in AD and that the DAergic system may be a rational target for pharmacological treatment of apathy.
BACKGROUND:Alzheimer's disease (AD) is characterized by a number of serious and debilitating behavioral and psychological symptoms of dementia (BPSD). The most common of these BPSD is apathy, which represents a major source of morbidity and premature institutionalization in the AD population. Many studies have identified discrete changes to the dopaminergic (DAergic) system in patients with AD. The DAergic system is closely related to the brain reward system (BRS) and some studies have suggested that dysfunction in the DAergic system may account for symptoms of apathy in the AD population. METHOD: Changes to the dopamine (DA) system in AD will be reviewed, and evidence supporting the involvement of the DAergic system in the development of apathy will be examined. Additionally, some pharmacological interventions with DA activity have been identified. The utility of these treatments in the AD population will be reviewed, with a focus on apathy as an outcome. RESULTS: Evidence presented in this review suggests that DAdysfunction in discrete brain areas is an important correlate of apathy in AD and that the DAergic system may be a rational target for pharmacological treatment of apathy.
Authors: Paul B Rosenberg; Krista L Lanctôt; Lea T Drye; Nathan Herrmann; Roberta W Scherer; David L Bachman; Jacobo E Mintzer Journal: J Clin Psychiatry Date: 2013-08 Impact factor: 4.384
Authors: Constantine G Lyketsos; Maria C Carrillo; J Michael Ryan; Ara S Khachaturian; Paula Trzepacz; Joan Amatniek; Jesse Cedarbaum; Robert Brashear; David S Miller Journal: Alzheimers Dement Date: 2011-09 Impact factor: 21.566
Authors: N K Popova; A V Kulikov; E M Kondaurova; A S Tsybko; E A Kulikova; I B Krasnov; B S Shenkman; E Yu Bazhenova; N A Sinyakova; V S Naumenko Journal: Mol Neurobiol Date: 2014-08-02 Impact factor: 5.590
Authors: Krista L Lanctôt; Sarah A Chau; Nathan Herrmann; Lea T Drye; Paul B Rosenberg; Roberta W Scherer; Sandra E Black; Vijay Vaidya; David L Bachman; Jacobo E Mintzer Journal: Int Psychogeriatr Date: 2013-10-29 Impact factor: 3.878
Authors: Yonas E Geda; Rosebud O Roberts; Michelle M Mielke; David S Knopman; Teresa J H Christianson; Vernon S Pankratz; Bradley F Boeve; Ondrej Sochor; Eric G Tangalos; Ronald C Petersen; Walter A Rocca Journal: Am J Psychiatry Date: 2014-05 Impact factor: 18.112
Authors: Goran Šimić; Mirjana Babić Leko; Selina Wray; Charles R Harrington; Ivana Delalle; Nataša Jovanov-Milošević; Danira Bažadona; Luc Buée; Rohan de Silva; Giuseppe Di Giovanni; Claude M Wischik; Patrick R Hof Journal: Prog Neurobiol Date: 2016-04-12 Impact factor: 11.685
Authors: David C Consoli; Lillian J Brady; Aaron B Bowman; Erin S Calipari; Fiona E Harrison Journal: J Neurochem Date: 2020-09-21 Impact factor: 5.372